UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/603,400	05/23/2017	Paresh K. Patel	104402-5034-US	7796

24341 7590 11/18/2020

Morgan, Lewis & Bockius LLP (PA)
1400 Page Mill Road
Palo Alto, CA 94304-1124

EXAMINER	
POINVIL, FRANTZY	

ART UNIT	PAPER NUMBER
3691	

NOTIFICATION DATE	DELIVERY MODE
11/18/2020	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

padocketingdepartment@morganlewis.com
vskliba@morganlewis.com

Corrected ***Notice of Allowability***	**Application No.** 15/603,400	**Applicant(s)** Patel, Paresh K.	
	Examiner FRANTZY POINVIL	**Art Unit** 3691	**AIA (FITF) Status** Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☑ This communication is responsive to the Request for Continued Examination filed 2/24/2020.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

3. ☑ The allowed claim(s) is/are 1-25 . As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see **http://www.uspto.gov/patents/init_events/pph/index.jsp** or send an inquiry to **PPHfeedback@uspto.gov.**

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some *c) ☐ None of the:

   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____ .

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____ .

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 10/16/2020.
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material _____.
4. ☑ Interview Summary (PTO-413), Paper No./Mail Date. 11/13/2020.
5. ☐ Examiner's Amendment/Comment
6. ☐ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/FRANTZY POINVIL/
Primary Examiner, Art Unit 3691

Examiner-Initiated Interview Summary	Application No. 15/603,400	Applicant(s) Patel, Paresh K.		
	Examiner FRANTZY POINVIL	Art Unit 3691	AIA (First Inventor to File) Status Yes	Page 1 of 1

All participants (applicant, applicants representative, PTO personnel):

1. FRANTZY POINVIL (Primary Examiner); Telephonic

2. Douglas J. Crisman (Attorney); Telephonic

Date of Interview: 13 November 2020

Claims Discussed: 1-25

Prior Art Discussed: Arora et al.

Brief Description of the main topic(s) of discussion: 35 USC 103 rejection was discussed.

Issues Discussed:

Item(s) under 35 U.S.C. 103:
The identifying functions of claims 1, 8 and 9 were discussed and it was agreed that the Arora et al reference does not teach or suggest this claimed feature.

/FRANTZY POINVIL/ Primary Examiner, Art Unit 3691	

Applicant is reminded that a complete written statement as to the substance of the interview must be made of record in the application file. It is the applicants responsibility to provide the written statement, unless the interview was initiated by the Examiner and the Examiner has indicated that a written summary will be provided. See MPEP 713.04
Please further see:
MPEP 713.04
Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews, paragraph (b)
37 CFR § 1.2 Business to be transacted in writing

Applicant recordation instructions: It is not necessary for applicant to provide a separate record of the substance of interview .

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

Electronically filed October 16, 2020

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Paresh K. Patel et al	Confirmation No.:	7796
Serial No.:	15/603,400	Art Unit:	3691
Filed:	May 23, 2017	Examiner:	Poinvil, Frantzy
For:	Method and System for Presenting Representations of Payment Accepting Unit Events	Attorney Docket No.:	104402-5034US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:

1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.

1b. A legible copy of:

☐ Each foreign patent;

☐ Each publication or that portion which caused it to be listed on the PTO-1449;

☐ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;

☐ all other information or portion which caused it to be listed on the PTO-1449.

1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.

1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /F.P/

2. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):

☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);

☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;

☐ Before the mailing of the first Office action on the merits;

☒ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

3. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a, 3b, 3c or 3d)

3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.

3b. ☐ The $260 (large entity) fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c).

3c. ☐ The $130 (small entity) fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c).

3d. ☐ The $65 (micro entity) fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c).

(Items 3b or 3c to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

(Check Item 4a, and 4b, 4c or 4d)

4a. ☐ The Certification Statement in Item 5 below is applicable.

4b. ☐ The $260 (large entity) fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c).

4c. ☐ The $130 (small entity) fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c).

4d. ☐ The $65 (micro entity) fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /F.P/

5. ☐ Certification Statement (applicable if Item 3a or Item 4a is checked)

(Check either Item 5a, 5b, 5c or 5d)

5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

5b. ☐ In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this information disclosure statement.

5c. ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

5d. ☐ Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

6. ☒ Copies of each cited U.S. patent and each U.S. patent application publication are not enclosed pursuant to the USPTO OG Notice dated 05 August 2003 waiving the requirement under 37 C.F.R. 1.98(a)(2)(i) for U.S. patent applications filed after June 30, 2003.

7. ☐ This application is a continuation application under 37 C.F.R. §1.53(b) or (d).

(Check appropriate Items 7a, 7b and/or 7c)

7a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.

7b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. , filed on , of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).

7c. ☐ Copies of the publications listed on the attached Form PTO-1449 that were not previously cited in prior application Serial No. , filed on , are provided herewith.

8. ☐ This is a Supplemental Information Disclosure Statement. (Check Item 8a)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /F.P/

8a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .

9. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

(Check Item 9a, 9b, or 9c)

9a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.

9b. ☐ set forth in the application.

9c. ☐ enclosed as an attachment hereto.

10. ☒ Payment has been made via Financial Manager, however, the Director is hereby authorized to charge any required fees to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310 (order no. 104402-5034US).

11. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: October 16, 2020

/ Douglas J. Crisman / 39,951
Douglas J. Crisman (Reg. No.)
MORGAN, LEWIS & BOCKIUS LLP
1400 Page Mill Road
Palo Alto, CA 94304
(650) 843-4000

/FRANTZY POINVIL/

10/28/2020

07

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /F.P/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Substitute for Form 1449-PTO				Electronically filed October 16, 2020	
				Application Number	15/603,400
				Filing Date	May 23, 2017
				First Named Inventor	Paresh K. Patel
				Art Unit	3691
				Examiner Name	Poinvil, Frantzy
Sheet	1	of	1	Attorney Docket Number	104402-5034US

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		9,898,884 B1	02-20-2018	Arora et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code – Number - Kind Code *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

Examiner Signature	/FRANTZY POINVIL/	Date Considered	10/28/2020

DB2/ 22684197.4

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /F.P/

Electronically Filed November 13, 2020

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Paresh K. Patel	Confirmation No.:	7796
Serial No.:	15/603,400	Art Unit:	3691
Filed:	May 23, 2017	Examiner:	Frantzy Poinvil
For:	*Method and System for Presenting Representations of Payment Accepting Unit Events*	Atty. Docket No.:	104402-5034-US

SUBSTANCE OF INTERVIEW

The undersigned Applicant's representative thanks the Examiner for the opportunity to discuss, during telephone calls on November 9, 12 and 13, 2020, the QPIDS submission filed in the above-referenced application on October 16, 2020.

In particular, the Examiner and Applicant's representative discussed the allowed claims in view of the single reference cited in the QPIDS submission (Arora, U.S. Pat. No. 9,898,884). Applicant noted that portions of the Arora reference identified by the Examiner fail to teach or suggest at least some limitations of the allowed claims, such as the "identifying" limitation of claim 1. The Examiner agreed that the allowed claims appear to be allowable over the Arora reference pending his further consideration.

Respectfully submitted,

Date: November 13, 2020

/Douglas J. Crisman/ 39,951

Douglas J. Crisman (Reg. No.)
MORGAN, LEWIS & BOCKIUS LLP
1400 Page Mill Road
Palo Alto, CA 94304
(650) 843-4000